Saltar al contenido principal

ETHNOS_APP

Inicio • Búsqueda • Revistas • Lista 0

Yumiko Nakamura

Datos Biográficos

ID7966992
NOMBREYumiko Nakamura
NOMBRESYumiko
APELLIDONakamura
FIRMANAKAMURA Y
AFILIACIONESUniversity of Toyama
ORCID0000-0002-3440-1641
VERIFICADOSí
TOTAL DE OBRAS2
TOTAL DE CITAS0
TOTAL COMO AUTOR2
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2013
AÑO MÁS RECIENTE DE PUBLICACIÓN2019
ÍNDICE H0
  • Eculizumab improves fatigue in refractory generalized myasthenia gravis

    Open Access•Henning Andersen, Renato Mantegazza et al.•ARTICLE•Quality of Life Research•2019

    Compared with placebo, eculizumab was associated with improvements in perceived fatigue that strongly correlated with improvements in MG-specific outcome measures. Trial ID Registration: NCT01997229, NCT02301624

  • Gray Matter Changes in Subjects at High Risk for Developing Psychosis and First-Episode Schizophrenia

    Open Access•Kazue Nakamura, Tsutomu Takahashi et al.•ARTICLE•Frontiers in Psychiatry•2013

    The present study suggests that alteration of the anterior cingulate gyrus may be associated with development of frank psychosis. Further studies with a larger ARMS subjects would be required to examine the potential role of neuroimaging methods in the prediction of future transition into psychosis

Sin obras prominentes en esta página.

  • Gray Matter Changes in Subjects at High Risk for Developing Psychosis and First-Episode Schizophrenia

    Open Access•Kazue Nakamura, Tsutomu Takahashi et al.•ARTICLE•Frontiers in Psychiatry•2013

    The present study suggests that alteration of the anterior cingulate gyrus may be associated with development of frank psychosis. Further studies with a larger ARMS subjects would be required to examine the potential role of neuroimaging methods in the prediction of future transition into psychosis

  • Eculizumab improves fatigue in refractory generalized myasthenia gravis

    Open Access•Henning Andersen, Renato Mantegazza et al.•ARTICLE•Quality of Life Research•2019

    Compared with placebo, eculizumab was associated with improvements in perceived fatigue that strongly correlated with improvements in MG-specific outcome measures. Trial ID Registration: NCT01997229, NCT02301624

Medicine (2 obras) · Advanced Neuroimaging Techniques and Applications (1 obras) · Anterior cingulate cortex (1 obras) · Antibody (1 obras) · At risk mental state (1 obras) · Cognition (1 obras) · Complement system (1 obras) · Eculizumab (1 obras) · Functional Brain Connectivity Studies (1 obras) · Gray (unit (1 obras)

Ethnos_APP • Proyecto Open Source • Licencia MIT • Frontend v2.0.0 • Privacidad y Cookies • Documentación de la API: api.ethnos.app/docs • Código de la API: GitHub • DOI: 10.5281/zenodo.17049435 • Código del Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae